| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4352782 | Neuroscience Research | 2006 | 8 Pages |
Abstract
Hyperactivity of the corticotropin-releasing factor (CRF) system occurs in some patients with anxiety disorders and depression. Blockade of CRF1 and CRF2 receptors can underlie the anxiolytic effects of drugs. In the present investigation, in vivo and in vitro studies were designed to determine whether the anxiolytic drug etifoxine, known to enhance GABAergic synaptic transmission, behaves also as a CRF1 and CRF2 receptor antagonist.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Marc Verleye, Nathalie André, Jean-Marie Gillardin,